Deadline
Passed
Lead Plaintiff Deadline: November 20, 2020
Please Upload related files below
Fill in below.
Tell us the stocks you own using Snaptrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. Snaptrade only shares the tickers you own and your transaction history, not your account numbers. Using Snaptrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery- link your account with Snaptrade.
05
Nov 2019
14
Jul 2020
Throughout the class period defendants’ statements were materially misleading because the data Defendants possessed on its principle product candidate, NC318, showed a lack of efficacy and objective responses. Had the truth been revealed, the market would have seen that NC318 was not, in fact, effective in treating most tumor types, that the NC318 application was proving to be limited (if even useful at all), and, as a result, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.
In order to be included in the lawsuit, you must have incurred a loss on shares of Nextcure purchased during the class period listed above.
If you suffered a loss in Nextcure during the relevant time frame, you have until November 20, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.